BioNTech SE

🎗𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡 𝐞𝐧𝐝𝐬 𝐰𝐢𝐭𝐡 𝐚 𝐬𝐢𝐦𝐩𝐥𝐞 𝐫𝐞𝐦𝐢𝐧𝐝𝐞𝐫 𝐭𝐡𝐚𝐭 𝐞𝐯𝐞𝐫𝐲 𝐦𝐢𝐧𝐮𝐭𝐞 𝐜𝐨𝐮𝐧𝐭𝐬. Lung cancer remains the most common cancer worldwide.     𝐃𝐢𝐝 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰? 🫁 𝐋𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐨𝐟𝐭𝐞𝐧 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐬 𝐬𝐢𝐥𝐞𝐧𝐭𝐥𝐲  Early symptoms can be mild or go unnoticed, which is why many cases are diagnosed at advanced stages.    🧬 𝐋𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐢𝐬 𝐧𝐨𝐭 𝐨𝐧𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞  NSCLC accounts for about 87% of cases and SCLC about 13%. Both are biologically complex and often require new scientific approaches.    🔬 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐦𝐚𝐝𝐞 𝐛𝐮𝐭 𝐮𝐧𝐦𝐞𝐭 𝐧𝐞𝐞𝐝𝐬 𝐫𝐞𝐦𝐚𝐢𝐧  Significant progress has been made in treating certain sub-types of lung cancer, but there remains an urgent need for new treatment options that offer more durable outcomes.    Our ultimate goal is to translate science into meaningful survival benefits for many patients by addressing some of the biggest challenges in cancer treatment. Our investigational therapies in lung cancer span mRNA cancer immunotherapies, immunomodulators, and targeted therapies in form of ADCs, aiming to support and activate the immune system in complementary ways.  By deepening our understanding of how lung tumors interact with the immune system and which barriers limit effective responses, we aim to generate insights that may help guide future therapeutic approaches. Raising awareness is a start.  Driving innovation is the goal, 𝐛𝐞𝐜𝐚𝐮𝐬𝐞 𝐞𝐯𝐞𝐫𝐲 𝐦𝐢𝐧𝐮𝐭𝐞 𝐜𝐨𝐮𝐧𝐭𝐬.   #LungCancerAwarenessMonth #LungCancer #Oncology #CancerResearch #everyminutecounts 

𝐂𝐮𝐫𝐢𝐨𝐮𝐬 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐧𝐞𝐱𝐭 𝐰𝐚𝐯𝐞 𝐨𝐟 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲? 🗽 We had such an inspiring time giving a glimpse into our innovation engine and ideas during our R&D Innovation Series Day 2025 in the Big Apple, where we shared how we are advancing our oncology strategy and pipeline: 🧩 Our unique position to contribute to transforming cancer medicine through the power of combination – driven by our portfolio spanning innovative and next-generation assets across complementary therapeutic modalities. These include investigational next-generation immunomodulators, mRNA cancer immunotherapies, and targeted therapies.     🔍 Our aim to translate science into meaningful survival benefits for patients and to offer novel treatment options for patients across the full continuum of cancer – from early to late-stage disease. 🧪 Our decade-long, deep expertise in understanding cancer biology, immunological mechanisms and engaging the immune system with our clinical candidates to address cancer from various angles, showcased by clinical and pre-clinical data on boosting immune cells and different immune pathways. 🎯 A look into what comes next: multiple expected readouts for our late-stage oncology candidates in the year ahead, including for our combination approaches. We currently have more than 20 clinical trials in Phase 2 and 3.  #ScienceToSurvival #CancerResearch #BioNTech #Oncology

𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡’𝐬 𝐐𝟑 𝟐𝟎𝟐𝟓 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 We just reported a strong third quarter – strategically, financially and with regard to continued progress across our oncology pipeline.    🧭 Strategy  - 𝐏𝐮𝐛𝐥𝐢𝐜 𝐞𝐱𝐜𝐡𝐚𝐧𝐠𝐞 𝐨𝐟𝐟𝐞𝐫 𝐜𝐨𝐦𝐦𝐞𝐧𝐜𝐞𝐝 for all outstanding shares of CureVac    📊 Financials   - $𝟕𝟎𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐫𝐞𝐜𝐨𝐠𝐧𝐢𝐳𝐞𝐝 from the strategic collaboration with BMS  - 𝐅𝐘 ‘𝟐𝟓 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐠𝐮𝐢𝐝𝐚𝐧𝐜𝐞 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐝   🥼 Product and clinical pipeline  - Consequent 𝐞𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧 𝐨𝐟 𝐨𝐮𝐫 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 focusing on two priority programs:   ⠀⠀⠀o an anti-PD-L1xVEGF-A antibody candidate ⠀⠀⠀o investigational mRNA cancer immunotherapies - Multiple clinical data updates across the pipeline  - Approval of Pfizer and BioNTech’s variant adapted COVID-19 vaccine    👉 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/eiUmsg6S   #BioNTech #Oncology #Q3Results #InvestorRelations

🔬 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐱 𝐄𝐒𝐌𝐎 𝟐𝟎𝟐𝟓 We at #BioNTech joined the global oncology community at ESMO 2025 in Berlin. From early-morning sessions to late-night discussions and countless insightful conversations in between, our teams were part of the scientific exchange. Guided by our mission: Translating science into survival. We are advancing science with the aim of transforming how cancer is treated, based on our investigative therapeutic approaches across: ✔️mRNA cancer immunotherapies ✔️Next-generation immunomodulators ✔️Targeted therapies This year’s congress once again highlighted the importance of innovation, scientific excellence, and collaboration to help shape the next era of cancer medicine. 🎥 Thank you to our colleagues and partners on site and everyone who visited our booth. Together we moved one step further in our shared goal to help improve outcomes for people living with cancer. #ESMO25 #Oncology #CancerResearch #Science #Biotech

𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐢𝐬 𝐭𝐚𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐧𝐞𝐱𝐭 𝐬𝐭𝐞𝐩 𝐢𝐧 𝐢𝐭𝐬 𝐩𝐥𝐚𝐧𝐧𝐞𝐝 𝐚𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐂𝐮𝐫𝐞𝐕𝐚𝐜. 🤝 We announced the commencement of a public exchange offer for outstanding shares of CureVac, an important step in the previously announced acquisition. The all-stock acquisition of CureVac is expected to create long-term value for shareholders of both companies. 🔬 At #BioNTech, we aspire to transform how cancer is treated. This acquisition brings together two highly complementary companies, building on BioNTech’s proven track record and established position in the global mRNA industry.  𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞: https://lnkd.in/eAwKaW52 𝐏𝐥𝐞𝐚𝐬𝐞 𝐬𝐞𝐞 𝐬𝐥𝐢𝐝𝐞𝐬 2 𝐭𝐨 4 𝐟𝐨𝐫 𝐚 𝐜𝐚𝐮𝐭𝐢𝐨𝐧𝐚𝐫𝐲 𝐬𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭 𝐫𝐞𝐠𝐚𝐫𝐝𝐢𝐧𝐠 𝐟𝐨𝐫𝐰𝐚𝐫𝐝-𝐥𝐨𝐨𝐤𝐢𝐧𝐠 𝐬𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐚 𝐧𝐨𝐭𝐢𝐜𝐞 𝐭𝐨 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 𝐚𝐧𝐝 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐢𝐞𝐬 𝐡𝐨𝐥𝐝𝐞𝐫𝐬. #BioNTech #mRNA #CancerTherapy #Oncology

🤖 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐀𝐈 𝐃𝐚𝐲 𝟐𝟎𝟐𝟓: 𝐒𝐡𝐨𝐰𝐜𝐚𝐬𝐢𝐧𝐠 𝐰𝐡𝐞𝐫𝐞 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐦𝐞𝐞𝐭𝐬 𝐀𝐈 How can artificial intelligence accelerate drug discovery, optimize delivery, and enable precision medicine for patients?  Last week, we explored these questions during our second 𝐀𝐈 𝐃𝐚𝐲, hosted at London’s Science Museum, a location that reflects BioNTech’s deep roots in science. The program featured keynotes from Karim Beguir and Ugur Sahin, alongside sessions led by BioNTech and InstaDeep teams highlighting how we are applying AI along the value chain aimed at shaping the future of medicine.      🙏 A big thank you to all speakers, investors and analysts who participated as well as our colleagues who contributed to making this day a success.  🎥 Watch the full recording to gain more insights into our AI strategy and capabilities: https://lnkd.in/e3NYPJH5   #aiday #biontech #innovation

📢 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐱 𝐖𝐂𝐋𝐂 Today, we presented global Phase 2 data on our PD-L1xVEGF-A bispecific antibody candidate in extensive-stage small cell lung cancer. Our science-driven approach targets two key drivers of this disease in a single molecule and we continue to investigate the potential of this novel approach to overcome some of the biggest treatment challenges for patients with lung cancer. For us, every innovation we pursue starts with the needs of patients. For people with small cell lung cancer, the outlook is amongst the most challenging in oncology. [1] This aggressive tumor type is marked by rapid growth and resistance to therapy and often progresses within months. These realities underline the urgent need for more durable treatment options. That is why, together with our partner Bristol Myers Squibb, we are committed to translating science into meaningful survival benefits.  Read the full press release here: https://lnkd.in/eysMmtxi 𝑹𝒆𝒇𝒆𝒓𝒆𝒏𝒄𝒆𝒔:  [1] https://lnkd.in/drZed93P [2] https://lnkd.in/eUU_6662 

𝐆𝐫𝐞𝐞𝐭𝐢𝐧𝐠𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐖𝐨𝐫𝐥𝐝 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐨𝐧 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝟐𝟎𝟐𝟓 𝐢𝐧 𝐁𝐚𝐫𝐜𝐞𝐥𝐨𝐧𝐚. At #BioNTech, lung cancer is a key focus, with multiple trials across disease stages evaluating mRNA immunotherapies, next-generation immunomodulators and ADCs. Lung cancer is one of the most common cancers and the leading cause of cancer related deaths worldwide. [1] While progress has been made, lung cancer remains aggressive and new options are needed for patients still facing one of the most devastating prognoses in oncology. Lung cancer is fast-spreading and difficult to treat, with many cases detected only at an advanced stage. This underlines the urgent need to explore new approaches that may help improve patient outcomes. This is why, at BioNTech, every innovation starts with the needs of patients in mind. We are fully committed to advancing science and exploring new approaches that may help shape the future standards of care for people living with lung cancer. At #WCLC25 we will present data highlighting the progress of our oncology pipeline and our commitment to people with lung cancer. To address this, our investigational pipeline includes: 🧬 mRNA immunotherapies: teaching the immune system to better recognize tumors 🔬 Immunomodulators: addressing fundamental drivers of lung cancer in a single molecule 🥼 ADCs: precisely targeting tumor cells If you are at #WCLC, visit us at our booth #106 to learn more. #BioNTechatWCLC   𝑹𝒆𝒇𝒆𝒓𝒆𝒏𝒄𝒆: [1] https://lnkd.in/drZed93P

Originally from New Zealand, Jonathan Falconer is a Senior Director in our Legal team. He supports key transactions working closely with teams across various departments. What made him join BioNTech? The people. The mindset. The shared purpose. “You feel it in the way teams work, there's a real sense of support and ambition.” says Jonathan. A major milestone: BioNTech’s acquisition of AI company InstaDeep. A fast-paced project that brought colleagues from many functions together, aligning quickly, staying focused, and delivering under pressure. At #BioNTech, legal expertise is more than contracts and compliance. It's about being part of a mission that matters and working with people who make it possible. 𝑳𝒆𝒂𝒓𝒏 𝒎𝒐𝒓𝒆 𝒂𝒃𝒐𝒖𝒕 𝒐𝒑𝒆𝒏 𝒑𝒐𝒔𝒊𝒕𝒊𝒐𝒏𝒔: https://lnkd.in/eAJkcGuA #TeamBioNTech #WeAreBioNTech #EmployerBranding

𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡‘𝐬 𝐐𝟐 𝐔𝐩𝐝𝐚𝐭𝐞 Our Q2/2025 results reflect the consistent execution of our strategy with: 🔬 a focus on our two pan-tumor programs and their broad advancement, also into late-stage clinical development 🔍 continued significant investments in the research and development of our priority assets 🤝 the announcement of two strategic transactions to expand and complement our capabilities A huge thank you goes out to our teams, partners and all stakeholders for supporting and driving this momentum with us. #TeamBioNTech 👉 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/eSUtnYpC #BioNTech #Oncology #Q2Results #InvestorRelations